Stephen V Liu, MD

@StephenVLiu

Thoracic Oncologist, Chief of Heme/Onc @Georgetown @MedStarGUH, Head of Developmental Therapeutics @LombardiCancer, #DCLung26 #TexasLung27 #HereWeGo #LetsGoBucs

Georgetown, Washington, DC

medstarhealth.org/doctors/stephe…

Joined September 2011

Replies Reposts Media

Pinned
Stephen V Liu, MD
@StephenVLiu
Jul 19
Join us in Washington, DC on Saturday, October 10 for #DCLung26 - a 1-day, comprehensive, @IASLC endorsed, multidisciplinary, discussion-based lung cancer CME update! From trainee to seasoned professional, MD to RN, local or not - something for everyone! medstarhealth.org/dclung
3
Stephen V Liu, MD
@StephenVLiu
1h
Join us in Washington, DC on Saturday, October 10 for #DCLung26 - a one-day, comprehensive, multidisciplinary, discussion-based lung cancer CME update! Jillian Thompson, nurse practitioner, will lend her perspective on the treatment of EGFR NSCLC! medstarhealth.org/dclung
Stephen V Liu, MD
@StephenVLiu
Sep 18
Looking forward to contributing at #ESMO26 in Madrid with other #ESMOAmbassadors including thoracic stars @Alfdoc2 @marinagarassino @g_mountzios @herbloong @EMariamidze @APassaroMD @myESMO
ESMO - Eur. Oncology
@myESMO
Sep 18
ESMO is pleased to announce the #ESMOAmbassadors for #ESMO26. They will share scientific highlights, expert perspectives and insights on the latest research presented at #ESMO26 across tumour types and disciplines. 🔗Discover the Ambassadors: ow.ly/Lj2t50ZOkuo
1
Stephen V Liu, MD
@StephenVLiu
Sep 18
Join us in Washington, DC on Saturday, October 10 for #DCLung26 - a one-day, comprehensive, multidisciplinary, discussion-based lung cancer CME update! Dr. @kaushalpar moderates our session on SCLC, mesothelioma, and thymic cancers. Grab your spot now! medstarhealth.org/dclung
Stephen V Liu, MD
@StephenVLiu
Sep 18
5y follow up from phase II study of lorlatinib in ALK+ NSCLC @JTOonline. Shorter OS noted for EML4::ALK fusion variant 3 competed to variants 1 or 2 and with TP53 co-mutation.
Final Biomarker and Efficacy Analyses of Lorlatinib in Patients With ALK-Positive Advanced Non-Sm...
From jto.org
1